To our knowledge, this study is the first to explore the combinatorial potential of Sambucus nigra and albumin-decorated–nanostructured lipid carriers as new sustainable nanocarriers to support antitumour targeted therapy, particularly for the synergistic therapy of colon, ovarian, and/or breast cancer. The gene discussed is ALB; the disease is breast carcinoma.